Opsynvi (macitentan 10 MG / tadalafil 20 MG) Oral Tablet
- RxCUI
- 2677771
- RxNorm name
- Opsynvi (macitentan 10 MG / tadalafil 20 MG) Oral Tablet
- Display name
- Opsynvi (macitentan 10 MG / tadalafil 20 MG) Oral Tablet
- Full name
- Opsynvi (macitentan 10 MG / tadalafil 20 MG) Oral Tablet
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:02
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OPSYNVI | MACITENTAN AND TADALAFIL | Actelion Pharmaceuticals US, Inc. | 6945b183-18d3-40de-afd1-c88e33cc1a63 | 2025-04-11 | Boxed warning, Warnings, Adverse reactions | 2677771 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 6945b183-18d3-40de-afd1-c88e33cc1a63 | Opsynvi (macitentan 10 MG / tadalafil 20 MG) Oral Tablet | SY | 3 | These highlights do not include all the information needed to use OPSYNVI safely and effectively. See full prescribing information for OPSYNVI. OPSYNVI ® (macitentan and tadalafil) tablets, for oral use Initial U.S. Approval: 2024 | 20250411 |
| 6945b183-18d3-40de-afd1-c88e33cc1a63 | Opsynvi 10 MG / 20 MG Oral Tablet | PSN | 3 | These highlights do not include all the information needed to use OPSYNVI safely and effectively. See full prescribing information for OPSYNVI. OPSYNVI ® (macitentan and tadalafil) tablets, for oral use Initial U.S. Approval: 2024 | 20250411 |
| 6945b183-18d3-40de-afd1-c88e33cc1a63 | macitentan 10 MG / tadalafil 20 MG Oral Tablet [Opsynvi] | SBD | 3 | These highlights do not include all the information needed to use OPSYNVI safely and effectively. See full prescribing information for OPSYNVI. OPSYNVI ® (macitentan and tadalafil) tablets, for oral use Initial U.S. Approval: 2024 | 20250411 |